Pieris Pharmaceuticals (PIRS) Short Interest Ratio & Short Volume $13.60 -2.53 (-15.69%) (As of 12/13/2024) Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Pieris Pharmaceuticals Short Interest DataPieris Pharmaceuticals (PIRS) has a short interest of 23,600 shares, representing 1.82% of the float (the number of shares available for trading by the public). This marks a -7.45% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.2, indicating that it would take 1.2 days of the average trading volume of 45,988 shares to cover all short positions.Current Short Interest23,600 sharesPrevious Short Interest25,500 sharesChange Vs. Previous Month-7.45%Dollar Volume Sold Short$383,500.00Short Interest Ratio1.2 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares1,320,000 sharesFloat Size1,300,000 sharesShort Percent of Float1.82%Today's Trading Volume51,700 sharesAverage Trading Volume45,988 sharesToday's Volume Vs. Average112% Short Selling Pieris Pharmaceuticals? Sign up to receive the latest short interest report for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPIRS Short Interest Over TimePIRS Days to Cover Over TimePIRS Percentage of Float Shorted Over Time Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Pieris Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202423,600 shares $383,500.00 -7.5%1.8%1.2 $16.25 11/15/202425,500 shares $404,631.45 +13.3%2.0%1.2 $15.87 10/31/202422,500 shares $388,125.00 -16.0%1.7%1.1 $17.25 10/15/202426,800 shares $432,016.00 -2.2%2.0%0.2 $16.12 9/30/202427,400 shares $458,676.00 -24.7%2.1%0.2 $16.74 9/15/202436,400 shares $606,788.00 -24.6%2.8%0.3 $16.67 Get the Latest News and Ratings for PIRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/202448,300 shares $888,720.00 -2.2%3.7%0.4 $18.40 8/15/202449,400 shares $803,738.00 -51.4%3.7%0.4 $16.27 7/31/2024101,700 shares $1.69 million +887.4%7.7%0.8 $16.60 7/15/202410,300 shares $76,323.00 -42.5%0.8%0.1 $7.41 6/30/202417,900 shares $175,611.53 +32.6%1.5%1.1 $9.81 6/15/202413,500 shares $136,216.35 -20.6%1.1%1.1 $10.09 5/31/202417,000 shares $172,550.00 -31.5%1.4%1.2 $10.15 5/15/202424,800 shares $281,976.00 +93.8%2.0%1.7 $11.37 4/30/202412,800 shares $149,888.00 +4,166.7%1.1%0.9 $11.71 4/15/2024300 shares $4,080.00 -99.8%0.0%0 $13.60 3/31/2024134,100 shares $24,567.12 +222.4%N/A0.2 $0.18 3/15/202441,600 shares $7,030.40 -41.2%N/A0.1 $0.17 2/29/202470,700 shares $11,672.57 +6.8%N/A0.1 $0.17 2/15/202466,200 shares $10,505.94 -69.1%N/A0.1 $0.16 1/31/2024214,500 shares $39,661.05 +31.1%N/A0.4 $0.18 1/15/2024163,600 shares $29,268.04 +22.6%N/A0.3 $0.18 12/31/2023133,400 shares $24,278.80 -17.5%N/A0.2 $0.18 12/15/2023161,600 shares $26,680.16 +145.6%N/A0.3 $0.17 11/30/202365,800 shares $13,442.94 -3.1%N/A0.1 $0.20 11/15/202367,900 shares $15,725.64 -63.5%N/A0.1 $0.23 10/31/2023186,100 shares $44,273.19 -26.7%N/A0.1 $0.24 10/15/2023253,900 shares $72,006.04 -55.7%N/A0.1 $0.28 9/30/2023573,500 shares $170,903.00 -5.2%N/A0.2 $0.30 9/15/2023605,200 shares $188,822.40 -57.4%N/A0.2 $0.31 8/31/20231,420,000 shares $481,806.00 +35.2%N/A0.4 $0.34 8/15/20231,050,000 shares $252,420.00 -28.6%N/A0.3 $0.24 7/31/20231,470,000 shares $324,870.00 +293.8%N/A0.5 $0.22 7/15/2023373,300 shares $72,793.50 -84.6%N/A0.1 $0.20 6/30/20232,420,000 shares $400,510.00 +32.2%N/A1.6 $0.17 6/15/20231,830,000 shares $1.63 million -1.1%N/A1.4 $0.89 5/31/20231,850,000 shares $1.57 million +0.5%N/A2.6 $0.85 5/15/20231,840,000 shares $1.59 million -1.1%N/A3 $0.86 4/30/20231,860,000 shares $1.41 million +1.6%N/A5.4 $0.76 4/15/20231,830,000 shares $1.31 million -0.5%N/A6.8 $0.72Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 3/31/20231,840,000 shares $1.80 million +0.6%2.9%6.4 $0.98 3/15/20231,830,000 shares $2.67 million No Change2.9%5.9 $1.46 2/28/20231,830,000 shares $2.75 million -0.5%2.9%5.6 $1.50 2/15/20231,840,000 shares $2.93 million -32.4%2.9%4.6 $1.59 1/31/20232,720,000 shares $4.35 million +70.0%N/A6.4 $1.60 1/15/20231,600,000 shares $2.40 million +0.6%N/A4.2 $1.50 12/30/20221,590,000 shares $1.65 million -4.2%N/A4.9 $1.04 12/15/20221,660,000 shares $1.63 million +0.6%N/A6.5 $0.98 11/30/20221,650,000 shares $1.61 million No ChangeN/A7.4 $0.98 11/15/20221,650,000 shares $1.61 million +1.9%N/A7.3 $0.98 10/31/20221,620,000 shares $1.80 million +14.1%N/A10 $1.11 10/15/20221,420,000 shares $1.42 million -4.7%2.3%8.4 $1.00 9/30/20221,490,000 shares $1.71 million +8.8%2.4%8 $1.15 9/15/20221,370,000 shares $1.89 million +5.4%2.2%6.8 $1.38 8/31/20221,300,000 shares $1.90 million -3.0%2.1%5.7 $1.46 8/15/20221,340,000 shares $2.29 million +9.8%2.1%5.1 $1.71 7/31/20221,220,000 shares $2.15 million +1.7%1.9%3.7 $1.76 7/15/20221,200,000 shares $2.26 million +3.5%1.9%3.3 $1.88 6/30/20221,160,000 shares $2.17 million +6.4%1.9%3.1 $1.87 6/15/20221,090,000 shares $1.80 million +18.0%1.7%2.7 $1.65 5/31/2022923,900 shares $1.64 million +45.3%1.5%2.3 $1.78 5/15/2022635,700 shares $1.09 million -11.8%1.0%1.5 $1.71 4/30/2022720,700 shares $2.02 million +12.6%1.2%1.7 $2.80 4/15/2022640,000 shares $2.01 million -42.9%1.0%1.4 $3.14 3/31/20221,120,000 shares $3.39 million +86.0%1.8%2.1 $3.03 3/15/2022602,200 shares $1.80 million -13.4%1.0%0.8 $2.99 2/28/2022695,100 shares $2.15 million +18.4%1.1%0.8 $3.09 2/15/2022587,100 shares $2.00 million -13.5%1.0%0.7 $3.40 1/31/2022678,500 shares $2.47 million -7.7%1.1%0.8 $3.64 1/15/2022734,900 shares $2.56 million -6.8%1.2%0.8 $3.49 12/31/2021788,700 shares $2.98 million +69.4%1.3%0.9 $3.78 12/15/2021465,500 shares $1.52 million -20.9%0.8%0.5 $3.26 11/30/2021588,800 shares $1.94 million -15.2%1.0%0.6 $3.30 11/15/2021694,000 shares $2.70 million -75.4%1.2%0.6 $3.89 10/29/20212,820,000 shares $12.92 million +75.2%4.7%2.1 $4.58 10/15/20211,610,000 shares $7.26 million +49.1%2.9%1.2 $4.51 9/30/20211,080,000 shares $5.58 million -1.8%1.9%0.7 $5.17 9/15/20211,100,000 shares $6.12 million +10.6%2.0%0.4 $5.56 8/31/2021994,200 shares $5.36 million -9.6%1.8%0.3 $5.39 8/13/20211,100,000 shares $4.22 million -47.6%2.0%0.1 $3.84 7/30/20212,100,000 shares $7.31 million -30.0%3.8%0.2 $3.48 7/15/20213,000,000 shares $10.56 million -11.2%5.8%0.3 $3.52 6/30/20213,380,000 shares $12.95 million -14.4%6.5%0.3 $3.83 6/15/20213,950,000 shares $13.79 million -44.0%7.6%0.4 $3.49 5/28/20217,050,000 shares $24.25 million +173.3%13.5%0.8 $3.44 5/14/20212,580,000 shares $4.82 million -8.5%N/A0.4 $1.87 4/30/20212,820,000 shares $6.23 million +10.6%6.0%4.5 $2.21 4/15/20212,550,000 shares $5.33 million +0.4%5.4%4.4 $2.09 3/31/20212,540,000 shares $6.35 million +8.1%N/A4.9 $2.50 3/15/20212,350,000 shares $6.20 million -6.4%N/A6 $2.64Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 2/26/20212,510,000 shares $7.03 million +8.2%N/A6.1 $2.80 2/12/20212,320,000 shares $6.80 million +13.2%N/A5.9 $2.93 1/29/20212,050,000 shares $5.23 million -1.0%N/A6 $2.55 1/15/20212,070,000 shares $5.78 million -3.7%N/A5.8 $2.79 12/31/20202,150,000 shares $5.70 million +9.7%N/A6.3 $2.65 12/15/20201,960,000 shares $5.23 million +5.4%N/A5.3 $2.67 11/30/20201,860,000 shares $5.49 million -7.9%N/A4.8 $2.95 11/15/20202,020,000 shares $5.51 million -8.2%N/A5.4 $2.73 10/30/20202,200,000 shares $5.37 million +26.4%N/A5.4 $2.44 10/15/20201,740,000 shares $4.15 million -3.9%N/A3.8 $2.39 9/30/20201,810,000 shares $3.75 million -1.1%N/A3.6 $2.07 9/15/20201,830,000 shares $5.38 million -2.7%N/A3.6 $2.94 8/31/20201,880,000 shares $5.38 million -1.6%N/A4 $2.86 8/14/20201,910,000 shares $5.83 million -1.0%N/A3.8 $3.05 7/31/20201,930,000 shares $4.96 million -16.8%N/A3.9 $2.57 7/15/20202,320,000 shares $6.80 million +2.7%N/A5.7 $2.93 6/30/20202,260,000 shares $7.21 million +16.5%N/A6.3 $3.19 6/15/20201,940,000 shares $5.90 million -4.9%N/A5.1 $3.04 5/29/20202,040,000 shares $7.34 million +4.1%N/A4.4 $3.60 5/15/20201,960,000 shares $5.47 million +9.5%N/A4.3 $2.79 4/30/20201,790,000 shares $4.74 million +1.1%N/A4 $2.65 4/15/20201,770,000 shares $4.57 million +0.6%N/A3.3 $2.58 3/31/20201,760,000 shares $5.00 million +25.2%N/A3.2 $2.84 3/13/20201,405,300 shares $3.56 million -5.7%N/A2.9 $2.53 2/28/20201,490,000 shares $3.11 million +8.8%N/A3 $2.09 2/14/20201,370,000 shares $3.52 million -16.0%2.9%2.7 $2.57 1/31/20201,630,000 shares $5.56 million +38.1%3.4%2.8 $3.41 1/15/20201,180,000 shares $4.72 million -32.6%2.4%2.1 $4.00 12/31/20191,750,000 shares $5.65 million -6.9%3.6%3.3 $3.23 PIRS Short Interest - Frequently Asked Questions What is Pieris Pharmaceuticals' current short interest? Short interest is the volume of Pieris Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 23,600 shares of PIRS short. 1.82% of Pieris Pharmaceuticals' shares are currently sold short. Learn More on Pieris Pharmaceuticals' current short interest. What is a good short interest ratio for Pieris Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PIRS shares currently have a short interest ratio of 1.0. Learn More on Pieris Pharmaceuticals's short interest ratio. What is a good short interest percentage for Pieris Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.82% of Pieris Pharmaceuticals' floating shares are currently sold short. Is Pieris Pharmaceuticals' short interest increasing or decreasing? Pieris Pharmaceuticals saw a drop in short interest during the month of November. As of November 30th, there was short interest totaling 23,600 shares, a drop of 7.5% from the previous total of 25,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Pieris Pharmaceuticals' float size? Pieris Pharmaceuticals currently has issued a total of 1,320,000 shares. Some of Pieris Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pieris Pharmaceuticals currently has a public float of 1,300,000 shares. How does Pieris Pharmaceuticals' short interest compare to its competitors? 1.82% of Pieris Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Pieris Pharmaceuticals: Annovis Bio, Inc. (9.49%), Repare Therapeutics Inc. (2.00%), OptiNose, Inc. (4.88%), Vistagen Therapeutics, Inc. (1.70%), DBV Technologies S.A. (1.82%), BioAtla, Inc. (8.23%), Cue Biopharma, Inc. (1.58%), SELLAS Life Sciences Group, Inc. (12.86%), InterCure Ltd. (0.14%), Oncolytics Biotech Inc. (2.97%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Pieris Pharmaceuticals stock? Short selling PIRS is an investing strategy that aims to generate trading profit from Pieris Pharmaceuticals as its price is falling. PIRS shares are trading down $2.53 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pieris Pharmaceuticals? A short squeeze for Pieris Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PIRS, which in turn drives the price of the stock up even further. How often is Pieris Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PIRS, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies ANVS Short Squeeze RPTX Short Squeeze OPTN Short Squeeze VTGN Short Squeeze DBVT Short Squeeze BCAB Short Squeeze CUE Short Squeeze SLS Short Squeeze INCR Short Squeeze ONCY Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PIRS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PIRS Stock Alerts